氟氢可的松在脓毒性休克中的剂量-反应关系:一项随机II期试验
这项多中心、开放标签、II期随机临床试验纳入153例脓毒性休克患者,比较单用静脉氢化可的松与联用三种剂量肠内氟氢可的松(50 µg、100 µg或200 µg每日)共7天的效果。主要终点为休克缓解时间,各组中位数均为3天,无显著差异。97%的患者在3小时可检出氟氢可的松血浆浓度,但个体差异大。28天死亡率在单用组为24%(9/38),50 µg组17%(7/42),100 µg组11%(4/36),200 µg组11%(4/37),组间无显著差异。
要点
- 在脓毒性休克患者中,加用肠内氟氢可的松50-200 µg/日并未比单用氢化可的松更早缓解休克,各组休克缓解时间中位数均为3天。
- 97%的患者在给药后3小时可检出氟氢可的松血浆浓度,中位浓度为261 ng/L(IQR 156-334),但浓度波动大,提示吸收和生物利用度存在差异。
- 28天死亡率在单用氢化可的松组为24%(9/38),50 µg组为17%(7/42),100 µg组为11%(4/36),200 µg组为11%(4/37),组间无显著差异。
- 各组在休克复发、器官衰竭指标及其他次要结局方面均无显著差异。
适用人群与场景
- 脓毒性休克患者,纳入多中心、开放标签、II期随机临床试验,共153例。
处置流程与药物剂量
- 静脉氢化可的松单用或联用肠内氟氢可的松50 µg、100 µg或200 µg每日,疗程7天。
研究设计与关键结果
- 多中心、开放标签、II期随机临床试验,纳入153例脓毒性休克患者,比较静脉氢化可的松单用(38例,25%)与联用肠内氟氢可的松50 µg(42例,27%)、100 µg(36例,24%)或200 µg(37例,24%)每日共7天。
- 主要终点休克缓解时间中位数(IQR)在氢化可的松单用组、50 µg组、100 µg组和200 µg组分别为3(2.5-4.5)天、3(2-4)天、3(2-6)天和3(2-5.5)天,组间无显著差异。
- 28天死亡率在氢化可的松单用组为24%(9/38),50 µg组为17%(7/42),100 µg组为11%(4/36),200 µg组为11%(4/37),组间无显著差异。
- 97%的患者在3小时可检出氟氢可的松血浆浓度,中位(IQR)261(156-334)ng/L,个体差异大。
- 休克复发、器官衰竭指标及其他次要结局组间均无显著差异。
证据类型、等级与局限
- 证据类型:多中心、开放标签、II期随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于脓毒性休克成人患者,在静脉氢化可的松基础上加用肠内氟氢可的松50-200 µg每日并未缩短休克缓解时间,原文结论不支持该联用可改善主要结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The combination of intravenous hydrocortisone and enteral fludrocortisone may reduce mortality in patients with septic shock. The optimal dose and reliability of absorption of fludrocortisone in critically ill patients are unclear.
METHODS: In a multi-centre, open label, phase II randomized clinical trial, intravenous hydrocortisone alone or in combination with one of three doses of enteral fludrocortisone (50 µg, 100 µg or 200 µg daily) for 7 days was compared in patients with septic shock. The primary outcome was time to shock resolution. We conducted pharmacokinetic studies to assess absorption.
RESULTS: Out of 153 enrolled patients, 38 (25%) received hydrocortisone alone, 42 (27%) received additional 50 µg, 36 (24%) received 100 µg and 37 (24%) received 200 µg fludrocortisone. Plasma concentrations of fludrocortisone were detected in 97% of patients at 3 h-median (interquartile range [IQR]) 261 (156-334) ng/L. There was no significant difference in the time to shock resolution between groups with median (IQR) of 3 (2.5-4.5), 3 (2-4), 3 (2-6) and 3 (2-5.5) days in the hydrocortisone alone, 50 µg, 100 µg and 200 µg fludrocortisone groups, respectively. The corresponding 28-day mortality rates were 9/38 (24%), 7/42 (17%), 4/36 (11%) and 4/37 (11%), respectively. There were no significant differences between groups with respect to, recurrence of shock, indices of organ failure or other secondary outcomes.
CONCLUSIONS: Enteral fludrocortisone resulted in detectable plasma fludrocortisone concentrations in the majority of critically ill patients with septic shock, although they varied widely indicating differing absorption and bioavailability. Its addition to hydrocortisone was not associated with shorter time to shock resolution.
参考来源
- Walsham J, Hammond N, Blumenthal A, et al. Fludrocortisone dose-response relationship in septic shock: a randomised phase II trial. Intensive Care Med. 2024. PMID: 39235623. doi:10.1007/s00134-024-07616-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。